Search results
15 maj 2024 · Despite the fact that a large number of drugs are now available to treat BPH, α-blockers have a significant impact on improvement in International Prostate Symptom Score (IPSS), maximum...
14 lis 2023 · This cohort study compares the cardiovascular safety profile of α-blockers vs 5-α reductase inhibitors for patients with benign prostatic hyperplasia.
15 maj 2024 · Current evidence supports α-blockers are effective in IPSS reduction and are considered safer. Larger sample size with long-term studies are needed to refine estimates of IPSS, QoL, PVR, and Qmax outcomes in α-blocker users. Keywords: Benign prostatic hyperplasia; International prostate symptom score; Network meta-analysis; Quality of life. © 2024.
Four long-acting alpha 1 blockers are approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, and alfuzosin. All are well tolerated and have comparable dose-dependent effectiveness. Tamsulosin and alfuzosin SR do not require dose titration.
Alpha-blockers were approved for the indication of BPH 24 years ago. Today, this class of drugs remains the first-line treatment of LUTS/BPH. The evolution of alpha-blockers has been to eliminate the requirement for dose titration and improve tolerability while preserving efficacy.
22 mar 2022 · Key points. •. Selective alpha-1 antagonists (eg, Tamsulosin) are safe, effective, and fast-acting first-line BPH treatment that targets voiding and storage LUTS. •. 5-alpha reductase inhibitors (eg, finasteride, dutasteride) are effective mono- or combination for men with large prostates and/or urinary retention. •.
1 cze 2023 · Studies that compared successful TWOC rates between each alpha-blocker regime in patients with AUR secondary to BPH were included. The outcome was the odds ratio of successful TWOC after AUR between groups (each regime of alpha blocker or placebo).
